The Paris Private Equity team advised Jeito Capital on fundraising for Jeito I, which garnered support from institutional investors and entrepreneurs totaling €200 million euros. Jeito I is an SLP, or French limited partnership, specializing in the financing of companies in the biotech and biopharmaceutical sectors, managed by Jeito Capital.
Jeito Capital is distinctive for its unique investment strategy, focusing on continuity from the beginning of clinical development to market access of breakthrough drugs that offer demonstrated human proof-of-concept. Jeito is a next-generation fund with a patient benefit driven approach, that focuses both on financing ground-breaking medical innovation and promoting positive societal impact.
For additional details, please read the press release.